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INTRODUCTION—There may be biologically relevant heterogeneity within typical late-onset
Alzheimer’s dementia.
METHODS—We analyzed cognitive data from people with incident late-onset Alzheimer’s
dementia from a prospective cohort study. We determined individual averages across memory,
visuospatial functioning, language, and executive functioning. We identified domains with
substantial impairments relative to that average. We compared demographic, neuropathology, and
genetic findings across groups defined by relative impairments.

Author Manuscript

RESULTS—During 32,286 person-years of follow-up, 869 people developed Alzheimer’s
dementia. There were 393 (48%) with no domain with substantial relative impairments. Some
participants had isolated relative impairments in memory (148, 18%), visuospatial functioning
(117, 14%), language (71, 9%), and executive functioning (66, 8%). The group with isolated
relative memory impairments had higher proportions with APOE ε4, more extensive Alzheimer’srelated neuropathology, and higher proportions with other Alzheimer’s dementia genetic risk
variants.
DISCUSSION—A cognitive subgrouping strategy may identify biologically distinct subsets of
people with Alzheimer’s dementia.
Keywords
Alzheimer’s disease; cognition; subgroups; endophenotypes; heterogeneity; genetics;
neuropathology

1. Introduction
Author Manuscript

There may be considerable heterogeneity in clinical presentation among people with
incident Alzheimer’s dementia begging the question of whether Alzheimer’s dementia in
older adults should be considered a single entity or meaningfully subdivided into distinct
disorders. Meaningfully subdividing a condition into distinct groups is essential to the
strategy of personalized medicine1–3. Data are currently lacking demonstrating a scalable
approach for meaningfully subdividing Alzheimer’s dementia.

Author Manuscript

Recent proposed guidelines identified atypical Alzheimer’s disease subtypes usually having
younger age of onset, including logopenic primary progressive aphasia, dysexecutive
Alzheimer’s disease, and posterior cortical atrophy4. Intriguingly, each of these subtypes is
associated with prominent impairment in a single non-memory domain – language,
executive functioning and visuospatial functioning, respectively – with relatively intact
memory performance. These previously identified atypical Alzheimer’s disease subtypes
may represent extremes of a spectrum of disease phenotypy.
We followed insights from neuropsychology, where practitioners have considered patterns of
relative impairments across cognitive domains to facilitate diagnosis since the earliest days
of the field5. We used cognitive data to determine the distribution at Alzheimer’s dementia
diagnosis for memory, language, executive functioning, and visuospatial abilities in a
community-based prospective cohort study. We determined individual averages across
domains, and identified domains with substantial impairments relative to that average. We
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defined subgroup membership based on which domains had relative impairments. We
compared demographic, neuropathology, and genetic findings across subgroups to test the
hypothesis that we could use cognitive data to identify biologically distinct late-onset
Alzheimer’s dementia subgroups.

2. Methods
We followed the STROBE guidelines (Appendix A)6. All steps are summarized in Appendix
B.
2.1. Study population

Author Manuscript

The source population for the Adult Changes in Thought (ACT) study consists of
community-living members of Group Health, a health maintenance organization in western
Washington State. A random sample of community-living Group Health members ≥65 years
old without established dementia diagnoses was invited to an enrollment visit in 1994–1996.
The Cognitive Abilities Screening Instrument (CASI) was administered. The CASI is a 100point scale that assesses several cognitive domains. Individuals with scores >85 were invited
to enroll. Those with scores of ≤85 were further evaluated with a neuropsychological battery
and comprehensive neurological evaluation. The neuropsychological battery included clock
drawing7, verbal fluency8, Mattis Dementia Rating Scale9, Boston naming8, verbal paired
associations and recall, logical memory and recall10, Word List Memory8, Constructional
Praxis and recall8, Trails A and B11, and Information and Comprehension subtest items10.

Author Manuscript

All cognitive and clinical data were reviewed in a multidisciplinary consensus conference to
determine dementia status; data from each case are discussed and forms with standardized
criteria are filled out. Composite scores were not available at the time of consensus
conferences and were not considered. Individuals free of dementia were invited to enroll in
the longitudinal study. Identical methods were used for an expansion cohort in 2000–2003.
In 2005 the study began continuous enrollment in which identical methods are used to enroll
new participants each month. This report considers all enrollees through April 2015, the
most recent data freeze.
Once enrolled, participants are administered the CASI every two years. The same
procedures are used to identify incident dementia12 and probable or possible Alzheimer’s
disease using NINCDS-ADRDA criteria13, referred to here as Alzheimer’s dementia.

Author Manuscript

Other than being a Group Health member, being free of dementia, and volunteering for a
longitudinal study, there are no additional inclusion or exclusion criteria for ACT. ACT
evaluates participants in their own homes or at a study clinic for study visits14.
We focus here on individuals who developed incident Alzheimer’s dementia. The derivation
of the analytic cohort is provided in Figure 1. The study was reviewed by Group Health and
University of Washington Institutional Review Boards. Participants gave written informed
consent.
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2.2. Ascertainment of subgroups
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An expert panel (ET, AS, and JM) considered each cognitive item and assigned each item to
a single cognitive domain – memory, visuospatial functioning, language, executive
functioning, or other. We used modern psychometric methods to obtain scores for each
domain. Composite scores have been recommended to address idiosyncrasies of individual
cognitive tests. Modern psychometric approaches have proven to have incrementally better
validity data than scores derived from standard approaches15–17, and they are specifically
recommended for genetic analyses18. We re-coded observed item responses to avoid sparse
response categories and limit to ≤10 response categories (see Appendix C–F). We used
Mplus 7.419 to fit confirmatory factor analysis single factor or bifactor models for each
domain separately. All scores were scaled to have mean 0 and standard deviation (SD) 1 in
all those with incident AD who had all four scores (n=825). Psychometric modeling details
for each domain are provided in Appendix C–F.

Author Manuscript

We determined each person’s average across the four cognitive domain scores. We
determined relative impairments by calculating differences between each domain score and
the individual’s average cognition score across domains. We evaluated candidate thresholds
to define “substantial” relative impairments ranging from 0.40 to 1.25 points at 0.05-point
increments. For each candidate threshold, we classified people as having 0, 1, or ≥2 domains
with substantial relative impairments; we further divided those with 1 domain according to
which domain was relatively impaired. This approach is illustrated in Box 1, where we
analyze domain scores for a made-up person and for two real people from ACT diagnosed
with atypical Alzheimer’s disease using the same methods described above. We further
illustrate performance on a single selected test from each domain in Box 2.

Author Manuscript

As discussed in Appendix G, we empirically selected a threshold of 0.75 points. We
compared characteristics of groups defined by that threshold.
2.3. Neuropathology procedures

Author Manuscript

ACT Neuropathology protocols are published20,21. We evaluated neurofibrillary tangles as
measured by Braak stage22, neuritic plaque frequency according to CERAD23, presence of
cerebral amyloid angiopathy, presence of hippocampal sclerosis, presence and location of
Lewy bodies categorized as present anywhere and as present in the amygdala, presence of
cystic infarcts, and presence and location of cerebral microinfarcts categorized as present
anywhere, in the cortex, or in deep structures (basal ganglia or thalamus). We present
findings for the group of ACT participants who died free of dementia, for everyone who died
following diagnosis of Alzheimer’s dementia, and separately for those in each cognitively
defined subgroup. ACT does not identify people with mild cognitive impairment (MCI);
people who died free of dementia could include some people with MCI. The neuropathology
results presented here exclude people who died with non-Alzheimer’s dementia.
2.4. Genetic data

APOE genotyping was available for most participants24. ACT participants with European
ancestry were included in the Alzheimer’s Disease Genetics Consortium (ADGC)24 and the
International Genomics of Alzheimer’s Project (IGAP)25 meta-analyses of genome-wide
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single nucleotide variant (SNV) associations with late-onset Alzheimer’s dementia.
Genotyping, quality control, and imputation procedures are detailed in those publications.
We used imputed genotype dosage data for the SNV with the highest level of association at
each of the 20 loci that achieved genome-wide significance in the Lambert et al. IGAP
paper25 (“IGAP SNVs”).
2.4. Statistical analyses
Group differences in descriptive findings were compared using linear or logistic regression,
as appropriate, and a categorical group variable with “no domain” identified as the reference.
We used similar models for autopsy findings, controlling for age at death, sex, and years of
education.

Author Manuscript

For genetic analyses, we used non-demented elderly individuals from ACT as the reference
group (some of these individuals could have had MCI), and included terms for age, sex, and
three principal components to account for population stratification. As in26, we did not
adjust for APOE genotype. We determined odds ratios for each IGAP SNV for all people
with Alzheimer’s dementia, and separately for each cognitively-defined subgroup.

3. Results
3.1. Characteristics of individuals with incident Alzheimer’s dementia

Author Manuscript

As of April 2015 ACT had enrolled 5,088 people, of whom 4,365 had at least one follow-up.
Over 32,286 person-years of follow-up (mean 8.1) 1,076 people developed dementia12, of
which 869 developed probable or possible Alzheimer’s disease by NINCDS-ADRDA
criteria13, referred to here as Alzheimer’s dementia. We had sufficient data to compute all
four cognitive domain scores for 825 (95%) of these; most of the remainder had only a
phone-based CASI without visuospatial functioning assessment.
On average people with Alzheimer’s dementia performed much worse than people with
normal cognition, especially for memory; see Box 2 for examples of test scores (one per
domain) alongside published normative data27,28. We used means and standard deviations
from the 825 people from ACT with incident Alzheimer’s dementia and all four domain
scores to define the metric (mean=0, SD=1) for each domain.

Author Manuscript

We identified a threshold of 0.75 points as a threshold indicating substantial relative
impairment (See Appendix G). At that threshold, there were 393 people (48%) who had no
domains with a substantial relative impairment. There were 396 people (48%) with a
substantial relative impairment in a single domain, including 148 with a substantial relative
impairment in memory (18%), 117 in visuospatial functioning (14%), 71 in language (9%),
and 66 in executive functioning (8%). The remaining 30 people (4%) had substantial relative
impairments in ≥2 domains.
Demographic characteristics of people with incident Alzheimer’s dementia in each
cognitively-defined subgroup are shown in Table 1, along with APOE genotype and
cognitive data. There were no important differences across groups in demographic
characteristics, including age at dementia onset. There were substantial differences in the
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proportion of people with incident Alzheimer’s dementia who had at least one APOE ε4
allele, ranging from 45% of those with isolated relative memory impairment to 22% of those
with isolated relative executive functioning impairment; the overall χ2 p-value for APOE
was 0.005.

Author Manuscript

Averages for cognitive scores are also shown in Table 1. For most groups, average CASI
total scores were similar to the overall average for people with incident Alzheimer’s
dementia, though they were somewhat higher for people with relative visuospatial
functioning impairments (p=0.01) and perhaps somewhat lower for those with relative
executive functioning impairments (p=0.61) and especially those with multiple domains with
relative impairments (p=0.02). The CASI total score includes 10 points for visuospatial
functioning and 12 points for executive functioning, so 10% of the total score is based on
executive functioning and 12% on executive functioning, while our average scores included
other measures of these domains and also assigned each of them to 25% of the total average
score.
By design, average scores across the entire group of people with incident Alzheimer’s
dementia for each cognitive domain were 0 with SD=1. People with no domains with a
substantial relative impairment had average overall scores and average domain scores that
reflected these patterns. The four groups made up of people with a single domain with
relative impairments had mean scores for the indicator domain about a full standard
deviation below average (about −1.0), while scores for the other domains were close to the
average (about 0.0) or a little better than the average. On average, the group with multiple
domains with relative impairments had lower scores on non-memory domains.
3.2. Autopsy findings

Author Manuscript

Autopsy findings are summarized in Table 2. Of the 825 people with incident Alzheimer’s
dementia and all four cognitive domain scores, 180 had died and come to autopsy at the time
of this report. We evaluated data from those individuals and people who died without a
diagnosis of dementia; people with non-Alzheimer’s dementia are not included in Table 2.

Author Manuscript

Most neuropathological findings were more common among people with Alzheimer’s
dementia than people with no dementia (all p <0.023, with the exception of Lewy bodies).
The frequency and mean severity of most neuropathological findings were similar across
cognitively-defined subgroups. Having a Braak stage of IV or higher was more common
among people with substantial relative memory impairment (91%) than among everyone
else with Alzheimer’s dementia (68%, p=0.003), and the proportion of people with amyloid
angiopathy was also higher, though this did not meet the traditional statistical significance
threshold (50% vs. 35%, p = 0.08).
3.3. Genetic findings
Genetic findings are summarized in Table 3. The fifth column of Table 3 shows odds ratios
(ORs) for the association between the 20 SNVs reported in Lambert et al.25 and Alzheimer’s
dementia case-control status in ACT. In general, findings in ACT were similar to those
previously reported25. The remaining 6 columns of Table 3 show ORs for the associations
between the 20 IGAP SNVs and case-control status, where “cases” were limited to
Alzheimers Dement. Author manuscript; available in PMC 2018 December 01.
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individuals in a cognitively-defined subgroup. While we were underpowered for genetic
association analyses with data from a single study, we nevertheless marked “extreme risk
ORs” (defined as OR>1.30) in shades of red, and “extreme protective ORs” (defined as
OR<1/1.30~0.77) in shades of blue.

Author Manuscript

ORs for those with no domain with substantial relative impairments were broadly similar to
those for the entire group of people with Alzheimer’s dementia, though there were
somewhat smaller ORs for the SNV associated with CR1 and MS4A6A, and somewhat
larger ORs for the SNVs associated with ABCA7 and CD33. For the subgroups of
individuals with a single domain with a substantial relative impairment, findings were quite
heterogeneous. There were eight extreme risk ORs for the group with an isolated relative
memory impairment. There were nine extreme risk ORs (6 risk, 3 protective) for the group
with an isolated relative visuospatial functioning impairment, and nine extreme risk ORs for
the group with an isolated substantial language impairment (4 risk, 5 protective). There were
six extreme risk ORs for the group with an isolated relative executive functioning
impairment (4 risk, 2 protective). The small group with multiple domains with relative
impairments had fifteen extreme risk ORs (nine risk, 5 protective).
There were several SNVs with extreme protective ORs for at least one cognitively defined
subgroup (blue cells) and extreme risk ORs for at least one other subgroup (red cells),
including SNVs associated with SORL1, FERMT2, CASS4, PTK2B, ZCWPW1, and
NME8.

4. Discussion
4.1. Key findings

Author Manuscript

We developed and implemented an approach to identify subgroups of people with typical
late-onset Alzheimer’s dementia on the basis of cognitive test data. We generated scores for
four domains – memory, visuospatial functioning, language, and executive functioning – and
characterized variation in these scores in a large group of people with incident Alzheimer’s
dementia. We determined each individual’s average level of cognition at Alzheimer’s
dementia diagnosis. We then determined differences from this average to identify domain(s)
with substantial relative impairments. About half of people with incident Alzheimer’s
dementia had no domains with a substantial relative impairment, and a similar number of
people had a single domain with a substantial relative impairment.

Author Manuscript

Demographic characteristics were similar across each of the cognitively defined subgroups,
including age at the time of Alzheimer’s dementia diagnosis. This point emphasizes a
distinction with the atypical Alzheimer’s disease subtypes such as posterior cortical atrophy
and primary progressive aphasia identified by the International Working Group4; each of
these is described as having an earlier age of onset than is typical for late-onset Alzheimer’s
dementia, and certainly earlier age of onset than the mid to late 80s as we found for each
subgroup and overall (see Table 1). These atypical Alzheimer’s disease subtypes may
occasionally be found in older adults, as demonstrated by the fact that there was one person
each with posterior cortical atrophy and with primary progressive aphasia in ACT (see Box
1). Our approach to categorizing people with typical late-onset Alzheimer’s dementia, when
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applied to those individuals with previously defined atypical Alzheimer’s disease subtypes,
worked precisely as one would wish – the person with posterior cortical atrophy had an
intact memory score and a substantial relative impairment in visuospatial functioning, while
the person with primary progressive aphasia had an intact memory score and a substantial
relative impairment in language (see Box 1). Additional analyses will be necessary to
determine relationships between people diagnosed with PPA, PCA, and dysexecutive
Alzheimer’s disease and people we identify with isolated substantial relative impairments in
language, visuospatial functioning, and executive functioning.

Author Manuscript

The group with isolated substantial memory impairment stood out from the other groups.
Using only cognitive testing data for our group assignments, we identified this group of 18%
of all people with incident late onset Alzheimer’s dementia who had a higher proportion
with APOE ε4 alleles (45% compared with 34% for everyone with Alzheimer’s dementia), a
higher proportion with Braak stage ≥4 (indeed, 91% of this group had Braak stage ≥4), and a
higher proportion with amyloid angiopathy. Furthermore, this group had eight of the IGAP
SNVs with ORs ≥1.30 – and they were all in the risk direction (all shades of red in Table 3).
Further analyses of this group are warranted.
The other subgroups appeared to be readily distinguishable from the group with isolated
substantial memory impairment and in terms of the pattern of findings across the SNVs they
were also distinguishable from each other. Larger sample sizes will be needed to make
firmer conclusions about those groups.
4.2. Possible explanations for findings

Author Manuscript

One possible explanation for these findings is that the strategy we implemented to group
people based on relative cognitive impairments works to identify biologically distinct
Alzheimer’s dementia subtypes. This explanation seems particularly well buttressed for the
group with substantial relative impairments in memory, where APOE genotype, Braak stage,
and seven IGAP SNVs had extreme ORs, all in the risk direction. The genetic data also
suggest support for possible biological relevance for the group with substantial relative
impairments in visuospatial functioning, where there were eleven IGAP SNVs with extreme
ORs.
Another possibility is that our observations do not reflect biologically distinct groups and
instead represent the play of chance. Replication in other samples will be very important to
differentiate between these two possibilities.
4.3. Implications of findings

Author Manuscript

If these findings are replicated in other samples, they suggest that a non-invasive, widelyavailable technology – cognitive testing – may differentiate people with Alzheimer’s disease
into biologically relevant distinct subgroups. In the future, combinations of cognitive testing
alongside other modalities such as structural MRI, CSF biofluids, or PET scans may be used
to identify subgroups of people with similar biological processes that are distinct from those
of people in other subgroups. Much work remains to be done; we are hopeful this work
represents initial steps towards a personalized medicine approach to Alzheimer’s dementia
therapeutics.
Alzheimers Dement. Author manuscript; available in PMC 2018 December 01.
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The ACT study includes a sample that reflects the demographic characteristics of the
surrounding community. We chose to categorize people based on data at their initial
Alzheimer’s dementia diagnosis, so disease duration (and thus likely severity) should not
vary much, though there may be differences in severity across subgroups even within this
timeframe. The sample is limited in terms of ethnic heterogeneity; the genetic analyses are
limited by design to people with European ancestry. The genetic findings are based on a
relatively small number of study participants. Replication in additional study samples will be
important. We were unable to evaluate differences in imaging parameters or in rates of
cognitive change over time with the data available to us.

Author Manuscript

We evaluated heterogeneity among people with clinical Alzheimer’s dementia based on
NINCDS-ADRDA criteria. It has long been appreciated that there is an imperfect correlation
between Alzheimer’s pathology and diagnoses of dementia and Alzheimer’s dementia, and
that other forms of pathology such as vascular brain disease play important roles29. We
found some differences in autopsy findings across cognitively-defined Alzheimer’s dementia
subgroups. Larger samples with autopsy data will be needed to more definitively investigate
the roles disparate neurodegenerative conditions may play in the heterogeneity of clinical
presentation.

Author Manuscript

The categorization scheme we developed borrows from principles that have been
instrumental in clinical neuropsychology for many years, since it considers patterns of
impairments, compared in this case to an individual’s overall ability level (as opposed to
their estimated premorbid ability). This approach successfully detected the individuals
diagnosed with primary progressive aphasia and posterior cortical atrophy from the ACT
study (see Box 1). These individuals can be considered “positive controls” to demonstrate
the success of the categorization approach. The categorization scheme is based entirely on
cognitive data, which is well tolerated and non-invasive. Most of our missing data were for
visuospatial functioning; people with visual impairments severe enough that their
visuospatial functioning cannot be assessed cannot be categorized using this approach.
Furthermore, the visuospatial functioning domain was limited by the data we had available
to form our composite scores. Future studies could investigate use of standard rather than
modern psychometric approaches to determine subgroup membership.

Author Manuscript

We used theory-driven approaches to categorize people with late-onset Alzheimer’s
dementia rather than computer-driven approaches such as cluster analysis. Cluster analysis
assigns people to categories that maximize distinctions between classes of people and result
in categories that may reflect clinical experience but also may not. Subsequent research
could compare our findings to those that would have been obtained with cluster analysis
approaches.
4.5. Conclusions
Here we describe development and implementation of an approach to categorize people at
the time of Alzheimer’s dementia diagnosis based on patterns of memory, visuospatial
functioning, language, and executive functioning. About half of those incident Alzheimer’s
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dementia had a single domain with a substantial relative impairment. Initial findings provide
some support for the notion that these subgroups may be biologically distinct. Further work
will be needed to replicate these findings.
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Box 1
Illustration of cognitively defined subgroup procedures
We determined scores for memory, visuospatial functioning, language, and executive
functioning. We determined each person’s average across domains at dementia diagnosis.
We determined differences from individual average scores.
Our first example case is a hypothetical individual:

Memory

Visuospatial
functioning

Language

Executive
functioning

Scores

0.00

0.00

0.00

−1.00

Average

−0.25

−0.25

−0.25

−0.25

Difference

+0.25

+0.25

+0.25

−0.75

Author Manuscript

This person scored at the ACT average among people with Alzheimer’s dementia for
memory, visuospatial functioning, and language, and scored 1 SD below average for
executive functioning (top row). This produces an average score of −0.25 (second row).
The third row shows differences from average for each domain, with a difference of
−0.75 for executive functioning, which would lead this person to be categorized in the
substantial executive functioning impairment subgroup.
Our second example case was a real individual with scores as shown below:

Author Manuscript

Memory

Visuospatial
functioning

Language

Executive
functioning

Scores

+1.02

−0.12

−1.02

−0.19

Average

−0.08

−0.08

−0.08

−0.08

Difference

+1.10

−0.04

−0.94

−0.11

This person’s average score was −0.08. Her memory score was quite a bit better than this,
while her language score was substantially worse (difference of −0.94 points). At the
ACT consensus conference, she was diagnosed with primary progressive aphasia, a
previously identified atypical Alzheimer’s disease subtype characterized by intact
memory and a substantial language impairment.
Our third example case was another real individual with scores as shown below:

Author Manuscript

Memory

Visuospatial
functioning

Language

Executive
functioning

Scores

+2.00

+0.21

+1.39

+0.26

Average

+0.96

+0.96

+0.96

+0.96

Difference

+1.04

−0.75

+0.44

−0.70

This person’s average score was +0.96. His memory score and language score were
higher than his executive functioning and visuospatial functioning scores. He was
diagnosed with posterior cortical atrophy, another previously identified atypical
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Alzheimer’s disease subtype characterized by intact memory and a substantial
visuospatial functioning impairment.
These examples demonstrate procedures used to determine cognitively-defined subgroups
of typical late-onset Alzheimer’s dementia. The real examples show how these
approaches work for one individual each with previously established atypical
Alzheimer’s disease subtypes.
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Box 2
Performance of people with Alzheimer’s dementia from the ACT study
compared to published normative data
Memory:
Logical
Memory
II from
the
WMS-R1

Visuospatial

Construction2

Language: Animal

Fluency2

Executive
functioning:
Trails B2

Raw Score Norms, Previously Published
Normal, 25th percentile

8–9

8.9

12.4

198

Normal, 50th percentile

1 1 – 13

10.2

15.3

150

16

10.9

18.5

109

Normal,

75th

percentile

Author Manuscript

Mean (SD) from people from ACT with incident Alzheimer’s dementia
All with AD

1.7 (2.6)

8.8 (1.7)

10.5 (3.9)

231*

0 domains with relative
impairment

1.4 (2.1)

8.9 (1.4)

10.4 (3.6)

257*

1 domain with relative impairment
Memory

0.1 (0.7)

9.7 (1.2)

10.7 (4.0)

166 *

Visuospatial

2.7 (3.1)

7.2 (2.0)

12.0 (4.2)

230 *

Language

3.2 (3.2)

9.3 (1.4)

8.8 (3.5)

225 *

Executive functioning

3.6 (3.2)

9.2 (1.3)

8.8 (3.3)

300*

3.5 (3.4)

8.0 (2.9)

10.8 (4.5)

300*

≥ 2 domains with
relative impairment
*Trails

Author Manuscript

B is terminated at 5 minutes (300 seconds). The median and 25th percentile for everyone with Alzheimer’s dementia and for each
of the subgroups was 300 seconds (it was 296 seconds for the group with single domain – memory). For example, for everyone with
Alzheimer’s dementia, the 25th percentile was 300, and the median was 300, while the 75th percentile was 231. We thus show only the 75th
percentile for people with Alzheimer’s dementia from ACT.

Author Manuscript

This table shows published normative data and data from people with incident
Alzheimer’s dementia from the ACT study for one indicator from each domain. For the
memory domain, scores for people with Alzheimer’s dementia are substantially lower on
Logical Memory II than published normative data for people over age 83 (median age
88)1. The group with substantial relative memory impairment had the very lowest
performance, as expected. For the other three tests, we show published data from
cognitively intact females aged 85–89 with >12 years education2, which is the modal
group for the ACT study. In the visuospatial functioning domain, construction was not
especially impaired for people with Alzheimer’s dementia compared with published
normative data, with the exception of the people with substantial relative visuospatial
functioning impairments. In the language domain, animal naming was substantially
impaired compared with published normative data across all groups of people with
Alzheimer’s dementia, and most profoundly among those with substantial relative
language impairments, but also among those with substantial relative executive
functioning impairments. In the executive functioning domain, Trails B was 300 seconds
(maximum value) for more than half of people with Alzheimer’s dementia in the ACT
study, and for at least three quarters of those in the isolated substantial executive
functioning group and the group with more than 1 domain with a substantial impairment.
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Research in Context
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1.

Systematic review: We reviewed PubMed literature sources on
endophenotyping in the context of Alzheimer’s dementia. We found many
papers on fluid and neuroimaging biomarker strategies, but none that
incorporated patterns of cognitive tests. We have contributed to the literature
considering differences between memory and executive functioning among
people with Alzheimer’s dementia to isolate people with prominent executive
dysfunction. We are not aware of studies that have also considered language
and visuospatial functioning as well.

2.

Interpretation: Our findings indicate that our cognitive subtyping strategy
identified groups that had heterogeneous neuropathological findings and
disparate relationships with genetic variants previously identified to be
associated with risk for late-onset Alzheimer’s dementia.

3.

Future directions: Future research is needed to replicate these findings in
other populations and determine whether a cognitive subtyping strategy may
be useful to isolate biologically relevant subsets of people with Alzheimer’s
dementia and thus used as an endophenotyping strategy
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Figure 1.

Derivation of the analytic sample.
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0.0 (0. 7)
0.0 (0.8)
0.0 (0.8)
0.0 (0.8)
0.0 (0.9)

79 (9)
0.0 (0.7)
0.0 (1.0)*
0.0 (1.0)*
0.0 (1.0)*
0.0 (1.0)*

Average cognition

Memory

Visuospatial functioning

Language

Executive functioning

78 (10)

121/340 (36%)

CASI

Cognitive scores

Any APOE ε4 alleles

14 (3)

86 (6)

77 (6)

248 (63%)

0.6 (0.8)

0.4 (0.9)

0.7 (0.7)

−0.9 (0.7)

0. 2 (0. 6)

7 9 (8)

60/130 (45%)

14 (3)

85 (6)

76 (7)

92 (62%)

Memory
(N=148), mean
(SD) or n (%)

0.1 (1.0)

0.3 (0.9)

−1.2 (0.9)

0.6 (1.0)

0.0 (0. 8)

81 (8)

28/100 (28 %)

14 (3)

86 (6)

78 (6)

77 (66%)

Visuospatial
functioning
(N=117), mean
(SD) or n (%)

0.0 (0.9)

−1.1 (0.9)

0.4 (0.9)

0.3 (1.0)

− 0.1 (0. 8)

80 (7)

15/60 (25%)

14 (3)

86 (5)

77 (6)

47 (66 %)

Language
(N=71), mean
(SD) or n (%)

Single domain impairment with relative

Scores were standardized to have a mean of 0 and SD 1 among people with Alzheimer’s disease who had all 4 scores.

*

14 (3)

Education

243/711 (34%)

86 (6)

Diagnosis age

APOE genotype

77 (6)

522 (63%)

Enrollment age

Female sex

Demographic characteristics

Characteristics

Overall
(N=825), mean (SD)
or n (%)

No domain with
relative impairment
(N=393), mean (SD)
or n (%)

−1.1 (0.8)

0.1 (0.9)

0.2 (0.9)

0.5 (0.9)

− 0. 1 (0. 7)

7 7 (8)

13/58 (22%)

13 (3)

85 (6)

76 (6)

37 (56%)

Executive
functioning
(N=66), mean (SD)
or n (%)

−0.8 (1.6)

−0.6 (1.4)

−0.4 (1.4)

0.3 (1.4)

− 0. 4 (0. 9)

74 (1 1)

6/23 (26%)

13 (4)

87 (6)

78 (6)

21 (70%)

Multiple domains
with relative
impairments
(N=30), mean (SD) or
n (%)

Demographic characteristics, APOE genotype, and cognitive scores across cognitively-defined subgroups of 825 people with incident Alzheimer’s
dementia
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81/293 (28%)
69/292 (24%)

Deep

72/178 (40%)

80/179 (45%)

99/179 (55%)

35/92 (38%)

42 (45%)

50 (54%)

35/92 (38%)

14/90 (16%)

19 (20%)

14 (15%)

33 (35%)

62 (67%)

2.1 (1.0)

63 (68%)

4.3 (1.7)

No domain with
relative
impairment
(N=93), mean
(SD) or n (%)

10 (31%)

15 (47%)

18 (56%)

12 (38%)

4/32 (13%)

5 (16%)

5/50 (17%)

16 (50%)

22 (67%)

2.0 (1.2)

29 (91%)

5.1 (1.4)

Memory
(N=32), mean
(SD) or n (%)

11/24 (46%)

10/24 (42%)

14/24 (58%)

12 (48%)

4/23 (17%)

4/24 (17%)

1/24 (4%)

7/24 (29%)

17 (68%)

1.9 (1.1)

16 (64%)

4.2 (1.5)

Visuospatial
functioning
(N=25), mean
(SD) or n (%)

8 (67%)

7 (58%)

9 (75%)

7 (58%)

0 (0%)

1 (8%)

2 (17%)

5 (42%)

8 (67%)

2.0 (1.2)

9 (75%)

4.4 (1.7)

Language
(N=12), mean
(SD) or n (%)

Single domain with relative impairments

7 (58%)

5 (42%)

6 (50%)

5 (42%)

2/11 (18%)

3 (25%)

2 (17%)

5 (42%)

8 (67%)

1.8 (1.3)

9 (75%)

4.4 (1.8)

Executive
functioning
(N=12), mean
(SD) or n (%)

1 (17%)

1 (17%)

2 (33%)

2 (33%)

0 (0%)

1 (17%)

1/5 (20%)

1 (17%)

3 (50%)

1.5 (1.0)

4 (67%)

4.2 (1.2)

Multiple domains
with relative
impairments
(N=6), mean (SD)
or n (%)

Denominators are specified in column heads unless indicated. CERAD scores are 0 (none), 1 (sparse), 2 (moderate), 3 (frequent), or 4 (severe). “Sufficient AD” refers to having a Braak stage at least 3 and
a CERAD level at least moderate.

*

100/293 (34%)

Cortex

73/179 (41%)

24/173 (14%)

31 / 275 (11%)

65/286 (23%)

33/179 (18%)

Any microvascular infarct

Microvascular infarcts

Cystic infarcts

Vascular brain injury

Amygdala

Any Lewy bodies

25/176 (14%)

67/179 (37%)

120 (67%)

2.0 (1.1)

130 (72%)

4.4 (1.6)

41 (14%)

17/283 (6%)

Lewy bodies

61/291 (21%)

Hippocampal sclerosis

71 (24%)

Sufficient AD*

Amyloid angiopathy

1.3 (1.1)

66 (22%)

2.8 (1.6)

CERAD level, mean (SD)

Braak Stage ≥4, n (%)

Braak Stage, mean (SD)

Alzheimer’s pathology, amyloid angiopathy, hippocampal sclerosis

Autopsy finding

No dementia
(N=294), mean (SD)
or n (%)

Total, all people
with Alzheimer’s
disease
(N=180), mean
(SD) or n (%)

Alzheimer’s disease

Autopsy findings for people with no dementia (n=294) and for people with clinical Alzheimer’s dementia (n=180)*
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0.41
0.31

CD33*

rs190982

rs3865444

1.06

1.08

1.08

1.08

1.08

1.10

1.10

1.10

1.10

1.11

1.11

1.11

1.14

1.14

1.15

1.15

1.16

1.18

1.22

1.30

1.18

1.22†

1.00

1.02

1.12

1.23†

1.03

1.19

1.33†

1.23

0.90

0.97

1.05

1.31†

1.11

1.18

0.89
1.28†

0.86

0.95

1.02

1.06

1.16

0.89

1.27

1.18

1.33

1.10

1.14

1.31

1.15

1.22

0.93

1.32

1.39

1.52

1.26

1.36

1.12

1.14

1.14

1.30†

1.24†

1.01

1.08

1.07

1.25

1.11

1.17

1.43†

1.02

1.69

Memory
(n=85)

0.85

1.12

1.29†
0.85

1.25

1.05

1.10

1.15

Overall
in ACT

1.39

1.23

1.26

0.71

0.94

1.44

0.98

1.28

0.82

1.07

0.76

1.12

1.67

1.39

0.96

1.13

0.71

1.65

1.17

1.39

Visuospatial functioning
(n=65)

0.95

1.14

0.66

0.98

1.26

1.38

0.98

0.96

1.20

1.05

1.31

1.19

0.80

1.12
0.57†

1.66†

1.65

1.41

0.62

1.04

1.44

0.99

1.44

0.92

1.45

0.64
1.47

0.95
0.55†

1.09

0.46

1.83

0.55

1.89

0.59

1.80

0.70

1.33

Multiple domains
with relative
deficits
(n=15)

1.45

0.84

0.59

1.30

1.20

0.94

1.12

0.98

0.78

1.01

Executive functioning
(n=37)

1.49

0.65

0.82

1.09

0.96

0.67

1.03

0.87

0.71

1.49

1.09

0.62

Language
(n=38)

Single domain with relative deficits

column shows the overall odds ratio for the ACT study. SNVs with a single dagger (†) had a nominal p<0.05 in the ACT study. The next six columns show odds ratios for each subgroup in the ACT study,
each compared with cognitively normal elderly controls. The color coding scheme is increasingly red for successively higher odds ratios (1.30–1.49 light pink, 1.50–1.74 medium pink, 1.75–1.99 dark pink,
≥2.00 dark red) and increasingly blue for successively lower odds ratios (0.77–0.67 turquoise, 0.66–0.58 light blue, 0.57–0.51 medium blue; <0.5, dark blue). We chose to mark ORs greater than 1.30 (or
less than 1/1.30~0.77) as that was the size of the largest OR reported in Lambert et al. (2014).

protective; we took the inverse of these protective odds ratios (marked with*) such that each odds ratio shown here is in the risk direction. We sorted SNVs in descending order of their odds ratios. The fifth

The first column shows the rs number for the 20 SNVs reported in Lambert et al. (2014) to be associated with late-onset Alzheimer’s dementia. The second column shows the closest gene to the tag SNV.
The third column shows the minor allele frequency (MAF) reported in Lambert et al. (2014). The fourth column shows the odds ratio (OR) reported in Lambert et al. (2014). Some minor alleles were

0.37

rs2718058

MEF2C*

0.32

NME8

0.49

CELF1

rs10948363

INPP5D

0.37

PTK2B

rs9271192

rs28834970

rs10838725

0.28

HLA-DRB5-HLA-DRB1

rs11771145

rs35349669

0.34

EPHA1*

rs983392

0.22

0.40

MS4A6A*

rs7274581

0.29

0.08

CASS4*

rs17125944

SLC24A4-RIN3*

0.09

FERMT2

rs10792832

rs1476679

0.36

PICALM*

rs4147929

rs10498633

0.19

ABCA7

rs9331896

0.27

0.38

CLU*

ZCWPW1*

0.20

CR1

rs6656401

CD2AP

0.41

0.04

BIN1

SORL1*

rs11218343

rs6733839

MAF

Gene

Reported
OR

Author Manuscript

rs number

No domain with
relative deficits
(n=217)
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Genetic findings (see note for details)
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